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Abstract
The hippocampus is an integral portion of the limbic system and executes a 
critical role in spatial and recognition learning, memory encoding, and memory 
consolidation. Hippocampal aging showed neurobiological alterations, including 
increased oxidative stress, altered intracellular signaling pathways, synaptic impair-
ment, and organelle deterioration such as mitochondrial dysfunction. These altera-
tions lead to hippocampal cognitive decline during aging. Therefore, the search 
for new non-invasive therapies focused on preserving or attenuating age-related 
hippocampal memory impairment could have of great impact on aging, consider-
ing the increasing life expectancy in the world. Red light Transcranial LED therapy 
(RL-TCLT) is a promising but little explored strategy, which involves red light LED 
irradiation without surgical procedures, safe and at a low cost. Nevertheless, the 
precise mechanism involved and its real impact on age-related cognitive impair-
ment is unclear, due to differences in protocol, wavelength applied, and time. 
Therefore, in this chapter, we will discuss the evidence about RL-TCLT and its 
effects on the hippocampal structure and function, and how this therapy could 
be used as a promising treatment for memory loss during aging and in age-related 
diseases such as Alzheimer’s Disease (AD). Finally, we will mention our advances in 
Red 630-light-Transcranial LED therapy on the hippocampus in aging and AD.
Keywords: aging, hippocampus, memory, LED therapy, mitochondria
1. Introduction
Aging is a biological process characterized by a general decline in cell function. 
Life expectancy is increasing and has turned aging into a social problem in the 
world. The brain is one of the organs that is most affected by age [1, 2], therefore 
new investigations into safe and non-invasive treatments to reduce age-related brain 
damage and subsequent cognitive impairment are of critical importance. The aging 
brain displays synaptic alterations that negatively affect cognitive capacity, especially 
memory. The hippocampus mediates the formation of new memories and age-
related hippocampal dysfunction compromises learning and memory processes [3].  
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Interestingly, in hippocampal memory loss, mitochondrial dysfunction plays a 
central role. Synaptic and mitochondrial dysfunction are early events in aging, mutu-
ally influenced, triggering age-associated memory defects [4]. Then, the need arises 
to find new strategies that can help elderly people to pass a better old age, without 
forgetting their memories or their history.
A promising but little explored strategy is the application of non-invasive cell 
stimulation with specific light types. Photobiomodulation is the use of light to 
stimulate or regenerate organs and tissues. Red-near-infrared (800-1100 nm) and 
red (600 nm) wavelengths of light-emitting diodes (LED) have been used for a 
range of therapeutic purposes [5–7]. These wavelengths could penetrate through 
the skin and have the potential to improve the cellular function of compromised 
tissue [5, 7]. Red-near-infrared and red LED therapy involves the interaction of 
photons with molecules in the cells [5, 8, 9]. Specifically, Transcranial LED therapy 
(TCLT) defines the limited application of LED therapy to the brain. The LED light 
travels through the layers of the scalp and skull to reach brain cells [10–12]. The 
brain is commonly irradiated with red (RL) or near-infrared (NIR) light (600-
1100 nm), with a total output power of 1-10,000 mW, a power density that has 
no thermal effects [9]. Several studies have reported the use of brain irradiation 
with red or near-infrared (600-1100 nm) LED improving tissue repair, blood flow, 
cicatrization, and recovery following trauma [12–14]; however, the results are 
variable due to differences in protocols and wavelengths, LED potential, stimula-
tion time the tissue target, the animal model used, as well as the doses or treatment 
period [13, 15–17].
Diverse experimental and clinical studies have been performed to test tran-
scranial LED therapy with promising results in brain function [9, 14, 16]. Thus, 
in vivo studies using 660 nm and 810 nm Red-light Transcranial LED therapy 
(RL-TCLT) in a mice model of aging induced by D-galactose in BALB/c mice 
improved spatial memory and increased mitochondrial function [18]. In trans-
genic AD mice, RL-LED treatment of the whole body recovered interstitial fluid 
flow, reduced Aβ deposition in the brain, and alleviate cognitive deficits [19]. 
Furthermore, studies in patients victims of severe traumatic brain injury (TBI) 
showed positive effects after RL-TCLT, enhancing their quality of life, by improv-
ing their memory, and decreasing affections such as pain, depression, nervous-
ness, and insomnia (Figure 1) [12, 20, 21].
Also, complementary in vitro studies with 600–850 nm LED irradiation 
showed light absorption by the cytochrome c oxidase (COX) enzyme, the complex 
IV of the oxidative phosphorylation (OXPHOS) system located in the electron 
transport chain (ETC) from the mitochondria [5], leading to the upregulation 
of the mitochondrial respiratory capacity and increased ATP production [4, 22]. 
In vitro assays also propose that mitochondrial COX act as a photoreceptor that 
mediates the beneficial effects of photobiomodulation [23]. Nevertheless, until 
is unclear how COX mediates the beneficial effect regulating energy production, 
and for this reason, most of the reports concluded that the mechanism underlying 
the neuroprotective actions of RL-TCLT is not completely understood. More stud-
ies are required to determine the biological events that lead to neuroprotection or 
neuronal repair.
In this chapter, we will summarize the evidence about the studies using Red 
Light Transcranial LED therapy (RL-TCLT), mainly focused on their positive 
effect in the brain, and particularly in the hippocampal structure and function. 
In addition, we will discuss the possible mechanisms involved in the beneficial 
effects of RL-TCLT, putting particular emphasis on the mitochondria. Finally, we 
will briefly comment on our main finding using RL-TCLT, as a potential anti-
aging therapy.
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2.  Red light transcranial LED therapy (RL-TCLT): types, devices, uses, 
an d effects
The use of transcranial photobiomodulation is promising in therapeutic and 
medical benefits for health, with increasing application and projection also in aging 
and neurodegenerative diseases [9, 24, 25]. The light presents different character-
istics that could be used advantageously in the field of health, principally by recent 
Figure 1. 
Beneficial effects of red and near-infrared light on the brain. Diverse reports have shown that irradiation 
of the brain with red and near-infrared light improves different conditions, including cerebral aging and 
age-related memory loss, stroke, depression, neurodegeneration in several neurodegenerative diseases, pain and 
trauma, tissue repair and cicatrization, and atrophy among others.
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lighting technologies based on an extensive range of diverse light sources, that have 
been used for photobiomodulation [8]. Light for therapeutic purposes corresponds 
to a small fraction of the spectrum of luminous radiation, generally in the visible 
spectrum [8, 25], where it has a biological effect based on the premise of mamma-
lian cellular metabolism from photoreceptors and chromophores molecules [25].
Diverse devices have been used, including Light Amplification by Stimulated 
Emission of Radiation (Laser) devices, Low-level light laser therapy, and light-
emitting diodes (LED) devices [26]. LED devices are semiconductors that present a 
high efficiency of electrical energy conversion into optical energy, dissipating little 
thermal energy [26]. Furthermore, these devices can have widely fluctuating power 
levels depending on the size, number, and power of the individual diodes [16, 27, 
28]. LED devices have been compared with lasers; however, devices irradiating LED 
are bandwidth (approx 40 nm), beam divergence, incoherent radiation emission, 
and high optical output power; favoring the absorption of energy by different 
molecular structures [5, 8]. In addition, LED devices have been considered as a 
safety by the US Food and Drug Administration (FDA) [29].
Red-Light Transcranial Led Therapy (RL-TLTC) involves power-efficient, low 
heat-producing light sources that have the potential to deliver high-intensity RL of 
600-690 wavelengths, that can be pulsed or continuous [30]. In this therapy, the 
light goes through the layers of the skin and skull, to stimulate the brain and specific 
cerebral regions, causing biological responses that result in benefits for the indi-
vidual [7, 8, 31]. In particular, RL-LED mediated a vibrational absorption process, 
which produces a photochemical effect that leads to the absorption of photons by 
specific molecules in the cell [5]. In addition, the wavelength (nm), energy density 
(J/cm2), and power density (mW/cm2) are parameters that determine the effective-
ness of RL-TLTC. The wavelength of light used is critical since not all ranges of light 
used have a similar effect, some ranges present reduced effects such as wavelength 
in the 700–750 nm range. In contrast, RL-LED at 600–690 nm or 760–900 nm has 
more impact on the biological tissues [5, 8]. Considering that these parameters 
of light radiation interact with biological tissue, they cause optical phenomena of 
reflection, transmission, propagation, and absorption. These characteristics also 
can present variations depending on tissue irradiated, for example by different 
concentrations of photoreceptor and chromophores molecules that contain biologi-
cal tissues, like water, cytochromes, and organic molecules as flavins, hemoglobin, 
and melanin, among others [5]. When light is absorbed, the photon energy reaches 
the target molecules producing vibrational, rotational, or electronic processes, 
which generate diverse effects including photochemical, photo-thermal, photo-
mechanical, or photo-electrical stimulation [5].
Interestingly, in the use of RL-TLCT, no standard protocol has been established 
in the literature; moreover, a few reports have shown studies using diverse param-
eters as varied wavelength ranges, time (sec/min), irradiance, or power density, and 
energy density with similar results, and important benefits in the brain health [5]. 
For example, studies applying Transcranial LED therapy bilaterally with wave-
lengths of 633 and 870 nm, have shown significant progress in both animals models 
with acute traumatic brain injury, and patients with acute stroke. In both cases 
also have been observed an improvement in the cognitive capacity post-treatment 
with this therapy [20]. Other studies using Low-level Laser Therapy (LLLT), with 
parameters of energy of 3 J/cm2, a wavelength of 810 nm, and power density of 
20 mW/ cm2, in primary cultured cortical neurons exposed to oxidative stress 
reveal that LLLT increased the mitochondrial membrane potential and reduced high 
ROS levels, reducing neuronal death [32]. Similarly, other studies showed that LLLT 
has a positive impact on neuronal function in both in vitro and in vivo, enhancing 
the metabolic capacity of neurons and cognitive functions including memory [14].
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Thus, while the transcranial research using RL LED or laser remains in the 
initial stages, growing evidence showed that although the RL and NIR-light therapy 
presents a wide range of characters, can modulate cell activity, including energy 
metabolism and cell function [25]. This is relevant since these therapies can lead 
to the improvement of pathological conditions and be in future significant clinical 
contribution, for example performing clinical treatments that allow helping older 
persons to prevent or mitigate the age-related cognitive impairment (Figure 1).
3. Effects of RL-TCLT on hippocampal structure and function
The effects of RL-TCLT on the nervous system, neuronal repair, and improv-
ing cognition are growing, and have been well-documented in cellular, animal 
models, and human studies [8]. Since the past decade, the use of RL-TCLT as an 
advanced and non-invasive therapeutic method in several brain-related condi-
tions has attracted interest from researchers in biomedical science, including those 
conditions or pathologies that manifest memory loss. Nevertheless, the underlying 
neural mechanisms are not well understood. The hippocampus is a brain structure 
of special importance in studying aging and cognitive decline, its main function is 
learning and memory [33]. It is a dorsoventrally elongated area, composed of the 
dentate gyrus (DG), the cornu ammonis (CA) fields CA1, CA2, and CA3, and the 
subiculum cortex [34]. The trisynaptic circuit is the main excitatory hippocampal 
synaptic pathway, formed by 3 neuronal groups: granule cells in the DG, and 
pyramidal neurons of the CA1 and CA3 [35]. This circuit receives inputs from the 
superficial layers of the entorhinal cortex via the perforant path to the DG. The DG 
projects to the CA3, which in turn projects to the CA1. Thus, CA1 projects to the 
deep layers of the entorhinal cortex, closing the circuit [33, 35, 36]. The hippocam-
pus mediates recognition and spatial memory, by a highly regulated circuit with a 
high-energy demand [37]. Besides, is important to highlight that the hippocampus 
is highly susceptible to factors such as mitochondrial dysfunction, stress, inflam-
mation, or physiological process such as aging, accumulating damage that gradually 
lead to a loss of hippocampal function [33].
Spatial memory gradually decreases with the age, since the hippocampus is criti-
cal for this type of memory, and the impairment of hippocampal neurons unequiv-
ocally results in spatial memory diminishing [37]. Studies from our and other 
groups have shown the reduced capacity of aged mice to learn and remember spatial 
tasks [4, 38, 39]. This is indicated by increased time to find a hidden platform in the 
Morris Water Maze (MWM) or a hidden chamber in the Barnes Maze (BM), two 
classic probes to evaluate hippocampus-dependent spatial memory [4, 22]. A report 
using the senescence-accelerated prone 8 (SAMP8) mice, a mouse model widely 
used to study oxidative impairment, and age-related brain damage, showed that 
RL-TCLT at 630 nm for two consecutive months prevents spatial memory loss in 5 
month-old (mo) SAMP8 mice, and more importantly rescued the cognitive deficits 
in SAMP8 mice of 7 mo [40]. This last was accompanied by reduced ROS levels in 
the brain and increased activity of antioxidant enzymes such as catalase and form-
aldehyde dehydrogenase [40]. Similarly, TCLT with NIR laser at 810 nm applied in 
mice exposed to acute sleep deprivation showed reduced hippocampal oxidative 
damage, increasing the activity of antioxidant enzymes, including superoxide dis-
mutase (SOD) and glutathione peroxidase (GPx) [16]. Additionally, several studies 
with cells, animals and in clinical trial conclude that RL-TCLT may have a potential 
effect on the brain since that has been observed that RL-TCTL protect nerve cells 
from a future impairment, reducing permanent neuronal damage and increasing 
their survival. For example, the treatment of K369I tau (K3) mice, a transgenic 
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mouse model of tauopathies and Alzheimer’s Disease, with NIR (600–1000 nm) 20 
times four weeks reveal a reduction in the size and number of amyloid-β plaques in 
the neocortex and hippocampus [41].
Besides, RL-TCLT may have a potential effect promoting both synaptogenesis 
and neurogenesis [42]. Both processes are essential to facilitating connectivity, 
neural regeneration, and generate structural changes that help to maintain exist-
ing neurons, and to encourage the growth of new neurons and synapses process 
[43, 44]. In this context, IR-light at 808 nm (350 mW/cm2 and 294 J) was applied 
in the scalp of a photothrombotic model of ischemic stroke in rats for seven days 
during 2-minute daily. The authors observed that IR-light therapy significantly 
attenuated behavioral deficits and infarct volume in cortical regions induced by 
photothrombotic stroke. This improvement was accompanied by neurogenesis 
and synaptogenesis, as is indicated by increased immunoreactivity of the prolif-
erative and differentiation markers BrdU, Ki67, DCX, MAP2, spinophilin, and the 
synaptic marker synaptophysin [45]. Also, other clinical studies reveal positive 
effects of transcranial LED therapy on cerebral blood fluid (CBF) in patients in 
a vegetative state or with major depression and anxiety. LED treatment by 20 
or 30 min per session, thrice per week over 6 weeks, or two times daily for over 
seventy days, with different wavelengths of 610, 627, and 810 nm increase CBF, 
improving cerebral vascular perfusion and reducing brain disorders [9, 46, 47]. 
Similarly, the application of TC-LLL therapy at 810-nm in mice model of corti-
cal impact and traumatic brain injury reveal increased proliferating neural cells 
around the lesion, possibly activating regenerative mechanisms such as induc-
ing neurogenesis in the dentate gyrus of the hippocampus [48]. Besides, they 
observed that the mice treated improved learning and memory reducing cognitive 
impairment [48, 49].
Thus, while its positive effects have been demonstrated countless times in ani-
mal models, they have yet to be proven in broad-scope clinical testing. However, the 
research that does exist is very promising, strongly indicating that RL-TCLT could 
be a viable treatment for a broad range of neurological diseases including stroke, 
traumatic brain injury, Parkinson’s disease, Alzheimer’s disease, and depression, in 
addition to providing cognitive enhancement for healthy subjects of advanced age 
that manifest cognitive impairment.
4.  Effects of RL-TCLT on synaptic neurotransmission and synaptic 
plasticity
Considering that irradiation with RL between 600 and 1200 nm produces 
changes at molecular, cellular, and tissue levels [50, 51] improving cognitive 
capacities [52], this enhancement in brain function will result in synaptic neuro-
transmission and synaptic plasticity potentiation after light treatment [53, 54]. 
Neurotransmission and synaptic plasticity represent the capacity of synaptic 
connections to adapt structurally and functionally in a stimulus-dependent manner 
[43]. Both synaptic neurotransmission and synaptic plasticity can be affected by 
different factors, such as mitochondrial dysfunction and increased oxidative stress, 
as well as physiological events including aging, stroke, brain injuries, or neuro-
degenerative disease, among others [22, 55, 56]. Therefore, treatments focused 
in maintain or promote neurotransmission and synaptic plasticity are attracting 
increasing attention. In this context, despite the beneficial effects showed for 
RL-TCLT on cognition, practically not exist electrophysiological studies using this 
therapy. As an approximation, we will discuss the studies using transcranial low-
level laser light (TC-LLL).
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Studies both in vitro and in vivo have shown that TC-LLL therapy supports neu-
ral function, this has been observed principally in reports using transgenic mouse 
models of Alzheimer’s disease (AD) [57]. Meng et al. observed that TC-LLL therapy 
at 632.8 nm in primary hippocampal neurons treated with full-length Aβ1–42 peptide 
reduced Aβ-induced neurotoxicity. In addition, TC-LLL therapy shows neuropro-
tective effects decreasing Aβ-induced dendrite atrophy [57]. Also, TC-LLL treat-
ment increased the expression of brain-derived neurotrophic factor (BDNF) in cell 
line and cultured neurons derived from APP/PS1 transgenic mice, suggesting that 
this neurotrophin will be modulating dendritic structure, promoting the survival 
of neurons and dendrite growth, and potentiating synaptic transmission in the 
CNS [57, 58]. All these results can be explained by the activation of the ERK/CREB/
BDNF pathway mediated by TC-LLL therapy [45] because this pathway is involved 
in the dendritic development of neurons [45, 57, 59]. Therefore, the TC-LLL therapy 
can induce activation of signaling transduction pathways, and gene transcription, 
which increases protein expression of different synaptic effectors and modulators, 
effects that also are potential therapeutic in treating neurodegenerative disease.
Interestingly, the NIR-LED light treatment at 670 nm in the Tg2576 mice model 
of AD, which progressively accumulated Aβ in their brain [60], indicate that NIR-
LED therapy decreased the levels of Aβ1–42 at the synapses and Aβ oligomer-induced 
reduction in long-term potentiation (LTP), relevant processes of neuroplasticity 
that correlates with memory formation [61]. Therefore, NIR-LED light therapy 
recovered crucial processes related to synaptic function, necessary to the preserva-
tion of cognition abilities [62]. Additionally, studies with photobiomodulation 
transcranial therapy with wavelengths of 635 nm in a mouse model of depression 
showed that this treatment reduces glutamate levels and neurotoxicity, improving 
the depressant behavior. These beneficial effects can be explained by the activation 
of the PKA pathway and the increased levels of the α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) receptors. In addition, reduce the expression of 
GluA1, decreasing the glutamatergic neurotransmission. Thus this therapy could 
rescue excitatory synaptic transmission, improve synaptic plasticity, and have also a 
potential anti-depressive effect [63].
Thus, several pieces of evidence suggest that the application of transcranial 
therapy light could be used to improve cellular components associated with the syn-
aptic function [42], which is essential in the maintenance and preservation of cog-
nition, including learning and memory [43]. In addition to the therapeutic effects at 
the molecular level, it is proposed the generation of changes at the behavioral level, 
such as cognitive improvement, antidepressant effects, and sleep improvement 
[42]. Furthermore, this therapy can stimulate neuronal organization or reorganiza-
tion, therefore it could be extremely promising as a method of stabilization and/
or improvement of various brain disorders or nervous system, and neurodegenera-
tive diseases [30, 42]. However, more extensive studies are necessary to evidence 
all the cellular and molecular mechanisms involved in these encouraging results. 
This last especially considering that the evidence summarized here consider severe 
differences in the device and light type used, the protocol of administration, and 
the study model. Is imperative to advance understanding the multiple targets of red 
light in the synaptic structure and function.
5. RL-TCLT mechanisms: improving mitochondrial function
Considering the multiple reports revised previously, now known that Red Light 
therapy, including Red and InfraRed LED light and Red Laser light, have favor-
able effects on brain structure and function, and especially in the hippocampus 
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improving cognitive functions [9, 25, 42]. This enhances in cognitive capacity could 
be explained by the activation of neurogenesis and synaptogenesis [9, 42], as well 
as by the stimulation of processes related to synaptic plasticity such as LTP [62]. 
However, any of these events reveal a potential mechanism by which Red light treat-
ment results therapeutic to different affections such as aging, neurodegenerative 
disease, stroke, and depression among others [42].
Interestingly, all pathological conditions mentioned previously involve, almost 
in part, dysfunction of hippocampal neurons attributable to mitochondrial defects 
[64, 65]. For example, mitochondrial dysfunction is considered a hallmark of aging 
and could be considered one of the factors leading to neurodegeneration [4, 22, 66]. 
Studies in humans and animal models showed that decreased memory correlates 
with reduced cerebral energetics metabolism and more specifically to mitochon-
drial bioenergetics deficits [4, 22, 66]. Therefore, the mitochondrial focus of aging 
and neurodegenerative diseases is of great interest for the development of a potent 
and ideally non-invasive anti-aging intervention to improve or attenuate cognitive 
impairment in the elderly.
Notably, enhanced metabolic functioning is one of the most identifiable proper-
ties of irradiate neuronal cells with RL or NIR light, resulting in increased intracel-
lular ATP production [8]. Thus, mitochondrial ATP production is one of the most 
strongly suggested mechanisms of action of RL therapy [5, 8]; for example, studies 
using RL-TCLT at 660 nm for 15 sec daily for 2 weeks in aged 18 mo mice improved 
ATP concentration [16]. More specifically, studies in vitro with RL and NRL LED 
radiations with a wavelength between 600 and 850 nm have shown that the effects 
of this treatment are principally attributed to photon absorption by complex IV of 
the mitochondrial respiratory chain [5]. This mitochondrial complex corresponds 
to the cytochrome c oxidase (COX) enzyme [22] and it seems that RL increases the 
activity of this enzymatic complex, leading to enhancement of oxygen consumption 
and ultimately to mitochondrial respiration [5]. COX is a photo acceptor of RL and 
NIR light, which generates a redox change in the enzyme [5, 8]. In turn, this causes 
a transient change in mitochondrial membrane potential (mψ) and increases ATP 
production [5, 16]. Thus, wavelengths corresponding or near to red will be improv-
ing the mitochondrial production of ATP, potentiating the synaptic and cognitive 
function [5, 42]. Nevertheless, is important to highlight that other works report 
that RL could inhibit the COX enzyme. In particular, NIR wavelengths of 750 nm 
and 950 nm reduced the activity of the COX complex. This results in decreased 
mitochondrial respiration and a loss of mitochondrial membrane potential (ΔΨm) 
[67]. Is surprising to note that the attenuation of mitochondrial function and the 
concomitant production of superoxide radical reduce neuronal death exposed to 
oxygen–glucose deprivation and in a mice model of ischemia, an effect that is not 
observed after other NIR wavelengths that activate COX [67]. Altogether, these 
contradictory results question the real effect of RL on COX responsible for the 
beneficial effects of this therapy (Figure 2).
On the other hand, several reports showed that RL-LED modulates the levels 
of reactive oxygen species (ROS) [30, 40]. Studies using RL-LED illumination at 
630 nm reduces brain H2O2 levels in cultured cells and the brain of SAMP8 mice 
[40]. This could be explained by an increment in the activity of antioxidant enzymes 
such as catalase or also could be a consequence of increased mitochondrial func-
tion with reduced electron leak [5, 16]; more studies are necessary to evaluate these 
possibilities. Besides, in this study, the authors showed that RL-LED absorption 
activates transcription factors that regulate long-lasting effects on gene expres-
sion [16], therefore this suggests that Red Light therapy could be a more complex 
mechanism, at a long time, and not only a transient activation of several enzymes. 
Other results also showed that Red 635 nm irradiation inhibits the expression of COX 
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enzyme, reducing ROS levels and mRNA of cytosolic phospholipase A2 (cPLA2) and 
secretary phospholipase A2 (sPLA2) [68]. This also consequently inhibits the release 
of PGE2, suggesting an additional anti-inflammatory effect (Figure 2).
Additional mechanisms that will be involved in the positive effects of RL-LED 
implicate Ca2+ ions modulation [8, 40]. RL and NIR LED are recognized by water 
groups formed in the heat/light-gated Ca+2 channel. This induces vibrational water 
energy, which in turn disorganizes the protein structure of the Ca+2 channel. This 
conformational change finally leads to channel opening; modulating intracellular 
Ca+2 levels [5]. This possible mechanism is relevant in neurons, considering that 
intracellular Ca+2 levels are critical to trigger survival or death pathways related to 
synaptic activity [69].
In summary, despite various mechanisms that could be mentioned such as the 
potential molecular target of RL and NRL, still is necessary additional research 
in the field to understand the events that result in synaptic and cognitive func-
tion. Possibly these improvements are the result of diverse events occurring 
simultaneously.
6.  Future perspectives of transcranial Red630-light-transcranial LED 
therapy preventing age-related memory loss: Our advances
Despite diverse studies shown possible molecular targets of RL-LED therapy  
[5, 8], the precise mechanism underlying the neuroprotective actions of RL-TCLT is 
not completely understood. Therefore, more studies are required to determine the 
Figure 2. 
Mechanism of action proposed to red and near-infrared light and its cellular effects. Transcranial therapy 
using red and near-infrared light has been proposed to photoactivate the cytochrome c oxidase (COX) enzyme, 
the complex IV of the electron transporter chain of the mitochondria. However other reports propose that 
several wavelengths inhibit COX enzyme; modulating ROS and ATP production, calcium homeostasis, and 
inflammatory processes.
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biological events that lead to neuroprotection or neuronal repair in both aging and 
neurodegenerative diseases. Possibly, the main problem related to the incapacity of 
determining a detailed mechanism is based on the variability of wavelengths, times 
of treatment, and models used [15, 16, 40, 63, 70]. Therefore, this highlights the 
need for complete studies using the same mice model, LED dispositive, and therapy 
protocol, to understand and describe the mechanism(s) underlying the benefits of 
RL-TCLT.
Interestingly, RL-TCLT at 630 nm in patients with traumatic brain injuries, using 
a helmet that emits radiation for 30 min, three times per week, for six weeks showed 
a great reduction in post-traumatic stress symptoms, insomnia, and depression, 
suggesting improved cognitive function [71]. More importantly, the same RL-TCLT 
used in aged patients with mild cognitive impairment improves memory in these 
aged humans. For this reason, and to study the complete effects and mechanisms 
of RL-TCLT in aging, we designed a unique RL-TCLT device to emit homogeneous 
light at a wavelength of 630 nm, with 100 J of energy, a power density of 0,35 w/
cm2, and an energy density of 43.5 J/cm2 in the brain of mice, specifically in the 
hippocampus.
We applied RL-TCLT to the hippocampus of 7.5mo SAMP8 mice, a mice model of 
accelerated aging, with an irradiation time of 125 s daily (excluding weekends) for 
5 weeks. This protocol is equivalent to the applied to patients with mild cognitive 
impairment described previously, and the mouse lifespan. We started the RL-TCLT 
in SAMP8 at 7.5mo because we and other authors showed that the non-transgenic 
SAMP8 mice present age-related hippocampal memory loss since 6mo and is more 
evident from 7mo onwards [72]. Interestingly, our results reveal that 7.5mo SAMP8 
mice treated with RL-TCLT at the hippocampus improves spatial learning and 
memory of aged SAMP8 mice. This cognitive improvement will be due to a possible 
remodeling of the synaptic structure toward more active synapses reducing the risk 
of excitotoxic events. This is suggested by i) an increase in presynaptic proteins such 
as synaptophysin (SYP) and Synapsin (SYN) that increase the neurotransmitter 
release [73], ii) a decrease in the NMDAR subunit NR2B, whose protein levels are 
related to excitotoxicity [74] and iii) higher Arc protein levels, a marker of synaptic 
plasticity [75] (Jara et al., manuscript in preparation).
Considering that both memory formation and synaptic activity are highly 
dependent on energy [76], that mitochondria are the main ATP producer of the 
cell [22], and that the suggested mechanisms by RL-TCLT target the mitochondria 
[5], we evaluated different mitochondrial functions in the hippocampus of treated 
SAMP8 mice with RL-TCLT. Relevantly, we observed increased ATP production, 
higher activity of the OXPHOS complex II-III, and IV (COX enzyme); suggesting 
that RL-TCLT directly stimulates mitochondrial bioenergetics function enhancing 
the activity of other OXPHOS complexes in addition to COX (Jara et al., manuscript 
in preparation). Similarly, we observed decreased levels of the mitochondrial cal-
cium uniporter (MCU), suggesting that it will result in reduced mitochondrial Ca+2 
overload and swelling, enhancing mitochondrial Ca+2 buffering. In fact, this last 
was validated in Ca+2 overload assays in hippocampal mitochondria from RL-TCLT 
SAMP8 mice (Jara et al., manuscript in preparation), indicating that RL-TCLT also 
improves the calcium buffering capacity of the aged hippocampal mitochondria. 
Whether bioenergetics and calcium buffering enhancing are directly related or are 
independent mechanisms requires future analysis.
Thus, our results indicated RL-LED-mediated mitochondrial stimulation, 
which could be transient or permanent. But it is difficult to think that only tran-
sient activation of mitochondrial function could explain the improved cognitive 
effects produced by RL-TCLT treatment. Although mitochondrial ATP produc-
tion is vital for synaptic communication, it is probably not solely sufficient to 
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result in improved hippocampal memory. Therefore, is highly probable that other 
mechanisms are involved in the beneficial effects of RL-TCLT, which result in gene 
transcription and the consequent cellular remodeling. In concordance with the 
anterior, we also observed higher PGC-1α protein levels, a transcriptional coactiva-
tor considered the main inducer of mitochondrial biogenesis that also regulates 
mitochondrial function [77]. This suggests that RL-TCLT will stimulate the gen-
eration of new mitochondria or the activation of gene-dependent mitochondrial 
reparation pathways that result in increased mitochondrial function. However, this 
requires a robust study.
7. Conclusions
In conclusion, despite the majority of treatments using RL-LED therapy are 
focused on cosmetic applications, RL-TCLT generates cellular effects that will be 
used to treat different affections including aging and neurodegenerative disease. 
For this, is necessary to be prudent to decide the more adequate wavelength, light 
intensity, and duration of therapy, because according to these parameters will found 
positive or negative effects. In addition, RL-TCLT seems to improve antioxidant 
defenses and mitochondrial function by enhancing COX IV activity. In concordance 
with these findings, we also propose that RL-TCLT stimulates mitochondrial func-
tion, both enhancing OXPHOS-mediated mitochondrial bioenergetics and calcium 
buffering capacity. Finally, we suggest that prolonged exposition to RL-TCLT result 
in a permanent remodeling of the cell, by a mechanism that involves gene transcrip-
tion, which results in higher synaptic and cognitive function. Future studies are 
extremely necessary to solve all the questions regarding the benefits of RL-TCLT.
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